Haixin Group: Subsidiary's Pharmaceutical Product Passes Generic Drug Consistency Evaluation

MetaMuskRat · 2026-03-18T08:50:02+00:00

People Finance News, March 16 – Haixin Stock (600851) announced on March 16 that its controlling subsidiary Gannan Haixin recently obtained an approval notice from the National Medical Products Administration for a supplementary application of the chemical drug lincomycin hydrochloride injection, with the drug passing the consistency evaluation of generic drug quality and efficacy. Lincomycin hydrochloride injection is applicable to serious infections caused by sensitive strains such as streptococci, pneumococci, and staphylococci, but is only suitable for patients allergic to penicillin or patients deemed unsuitable for penicillin use by physicians.

MetaMuskRat

2026-03-18 08:50:02

People’s Financial News, March 16 — Haixin Co., Ltd. (600851) announced on March 16 that its controlling subsidiary Gannan Haixin recently received the approval notice from the National Medical Products Administration for the supplemental application of the chemical drug Lincomycin Hydrochloride Injection. The drug has passed the consistency evaluation of quality and efficacy for generic drugs. Lincomycin Hydrochloride Injection is used for severe infections caused by sensitive bacteria such as Streptococcus, Pneumococcus, and Staphylococcus, but is only suitable for patients allergic to penicillin or for whom doctors determine penicillin should not be used.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes